Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics Biotechnologies GmbH (Immatics) and MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news